Intangible Assets, Net - Components (Details) - USD ($) $ in Thousands |
May 31, 2022 |
May 31, 2021 |
---|---|---|
Asset Acquisition [Line Items] | ||
Finite-Lived Intangible Assets, Gross | $ 3,520 | $ 6,446 |
Accumulated amortization, net of impairment | (3,388) | (4,793) |
Total amortizable intangible assets, net | 132 | 1,653 |
Website development costs | ||
Asset Acquisition [Line Items] | ||
Finite-Lived Intangible Assets, Gross | 20 | 20 |
Leronlimab (PRO 140) patent | ||
Asset Acquisition [Line Items] | ||
Finite-Lived Intangible Assets, Gross | $ 3,500 | 3,500 |
ProstaGene, LLC acquisition | ||
Asset Acquisition [Line Items] | ||
Finite-Lived Intangible Assets, Gross | $ 2,926 |
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|